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4 Abstract Electrospinning is a simple and versatile method to produce fibers using
5 charged polymer solutions. As drug delivery systems, electrospun fibers are an
6 excellent choice because of easy drug entrapment, high surface area, morphology
7 control and biomimetic characteristics. Various drugs and biomolecules can be
8 easily encapsulated inside or on fiber surface either during electrospinning or
9 through post-processing of the fibers. Multicomponent fibers have attracted special
10 attention because new properties and morphologies can be easily obtained through
11 the combination of different polymers. The factors that affect the drug release such
12 as construct geometry and thickness, diameter and porosity, composition, crys-
13 tallinity, swelling capacity, drug loading, drug state, drug molecular weight, drug
14 solubility in the release medium, drug–polymer–electrospinning solvent interac-
15 tions are discussed. Mathematical models of drug release from electrospun fibers
16 are reviewed and strategies to attain zero-order release and control of burst stage
17 are considered. Finally, some results concerning release control in bicomponent
18 fibers composed of poly(e-caprolactone) and Lutrol F127 (poly(oxyethylene-b-
19 oxypropylene-b-oxyethylene) are presented. The properties of the bicomponent
20 fibers were studied in order to determine the effect of electrospinning processing
21 on crystallinity, hydrophilicity and degradation. Acetazolamide and timolol
22 maleate were loaded in the fibers in different concentrations in order to determine
23 the effect of drug solubility in polymer, drug state, drug loading and fiber
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24 composition on morphology, drug distribution and release kinetics. Such elec-
25 trospun drug eluting fibers can be used as basic elements of various implants and
26 scaffolds for tissue regeneration.
27
28 1 What is Electrospinning?
29 Electrospinning is a method of producing fibers with diameters ranging from
30 micrometer to nanometer scale by accelerating a jet of charged polymer solution/
31 melt in an electric field. Recently, this technology has been expanding due to the
32 simplicity of the process and the various materials that can be used. Fibers can be
33 produced from either natural or synthetic polymers. Such fibers have diverse
34 applications including filtration, catalysis, textiles, composite materials, biomed-
35 icine (wound dressings, drug delivery, tissue engineering, cosmetics), sensors,
36 electronic devices, liquid crystals, photovoltaic cells and much more [1, 2].
37 Usually, the experimental set-up consists of a high voltage power supply
38 connecting an electrode with needle-like geometry (through which the polymer
39 solution is ejected) to the collector electrode. The polymer solution is pumped at
40 the desired flow rate using a syringe pump. A diagram presenting the most
41 common electrospinning set-up is shown in Fig. 1.
42 Recent works suggest that the most important mechanism of electrospinning is
43 a rapidly whipping/bending fluid jet [3]. The jet instability is produced by the
44 competition between surface tension and charge repulsion, in which the destabi-
45 lizing effect of charge repulsion is responsible for the stretching of the fluid jet and
46 simultaneous decrease in the jet diameter. Surface tension has a stabilizing effect
47 leading to the cessation of stretching and attaining a limiting terminal jet diameter.
48 The process can be decomposed into five components: fluid charging, formation of
49 the cone-jet, thinning of the steady jet, onset and growth of jet instabilities and
Fig. 1 Basic electrospining
set-up
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50 fiber collection [4]. Several process parameters (voltage, nozzle to collector dis-
51 tance, polymer flow rate, spinning environment) and solution parameters (con-
52 centration–viscosity, conductivity, surface tension, solvent volatility) can be
53 manipulated in order to obtain the desired properties of the fibers such as fiber
54 diameter and morphology. Moreover, the fibers can be collected with a multitude
55 of collectors producing fiber mats that contain either aligned or unoriented fibers
56 [5].
57 2 Electrospun Fibers as Drug Delivery Systems
58 Electrospun fibers have been shown to function as drug delivery systems because
59 of high surface area (which enhances mass transfer), similar topography and
60 porosity to the extracellular matrix making them ideal candidates as active
61 implants/scaffolds. The easy control of the macrostructure (oriented or arranged
62 randomly, fiber mat porosity) and the microstructure (individual fiber porosity)
63 will determine both the bulk physico-chemical properties and the biological
64 response to the implant/scaffold. Variuos drugs ranging from low molecular agents
65 to proteins and even cells [6] can be easily encapsulated inside or on the surface of
66 the fibers depending on the application. Some disadvantages include drug loading
67 that is limited by the drug solubility in the electrospining solution or burst effect
68 due to surface deposited drug.
69 Drug delivery systems can be classified according to different criteria [7, 8].
70 The most common one is to classify with respect to the rate control mechanism.
71 These classifications may also be applied to drug-containing polymeric fibers:
72 • Drug diffusion controlled systems: diffusion can take place either through the
73 bulk polymer as in bicomponent mixed fibers or through a barrier as in core–
74 shell fibers
75 • Solvent diffusion controlled systems: drug release is determined by the rate of
76 polymer swelling
77 • Chemically controlled systems: either polymer erosion or enzymatic/hydrolytic
78 polymer degradation control the drug release rate
79 • Regulated systems: the application of a magnetic field or another external
80 stimulus can trigger the release (as in composite fibers containing magnetic
81 particles)
82 The active ingredient can be loaded either during electrospinning or during
83 post-processing of the electrospun fibers. In the former case, the drug is either co-
84 dissolved with the polymers in the electrospinning solution or the drug is loaded in
85 particles that will be co-electrospun with the polymers [9–11]. The later case
86 includes various modalities of drug loading: fiber soaking in the drug solution,
87 drug impregnation using supercritical fluids technology [12], loading in previously
88 molecular imprinted fibers [13, 14], functionalization of the fiber surface through
89 grafting copolymerization [15] and subsequent drug/protein binding [16, 17].
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90 By electrospinning, the drug is usually entrapped as solid particles inside or on
91 the surface of the fibers. According to the type of solid–solid or polymer–drug
92 mixture, the drug loaded fibers can be classified as:
93 • Solid solutions: the drug is dissolved at molecular level in the polymer
94 • Solid dispersions: the drug is distributed in the polymer as either crystalline or
95 amorphous aggregates
96 • Phase-separated systems or reservoir systems: the drug is contained inside the
97 core of the fiber or encapsulated in particles, that are surrounded by a polymer
98 shell (as in core–shell constructs or composite fibers, see Sect. 2.1)
99 2.1 Multicomponent Fibers
100 Multicomponent fibers have attracted special attention because new properties can
101 be obtained through the combination of different materials. Synthetic polymers
102 with good processability and good mechanical properties can be mixed with
103 natural hydrophilic polymers producing an increase in cellular attachment and
104 biocompatibility [5]. Unfortunately, sometimes the solvent that is used to dissolve
105 both polymers can damage the structure of the natural polymer or phase separation
106 can worsen the mechanical properties. One possible solution is to incorporate
107 function-regulating biomolecules (DNA, growth factors) in synthetic polymers to
108 increase bioactivity [17] or to modify the structure of the polymer before elec-
109 trospinning [18].
110 Multicomponent fibers can be obtained mainly by two techniques [19, 20] as
111 shown in Fig. 2: electrospinning of polymers solution in a single-needle config-
112 uration (if a mixture of polymers is co-dissolved in the electrospinning solution) or
113 a multi-needle configuration (in which the polymer solutions are separated in
114 parallel or concentric syringes) and post-treatment of the electrospun fibers (which
115 can include either coating with other inorganic/polymer layers [16, 21], grafting
116 [15], crosslinking [22], chemical vapour deposition [23] or functionalization with
117 other (bio)polymers [17]).
118 In addition to the combination of physico-chemical properties that arise from
119 using various components, there can be obtained a variety of fiber morphologies as
120 presented in Fig. 3 such as core–shell fibers, micro/nanotubes, interpenetrating
121 phase morphologies (matrix dispersed or co-continuous fibers) [24, 25], nanoscale
122 morphologies (spheres, rods, micelles, lamellae, vesicle tubules, and cylinders)
123 obtained by self-assembly of block copolymers [26], multilayers (either with
124 different composition or different fiber diameter) [27, 28]. Moreover, the fiber
125 morphology can be further controlled after electrospinning by selective removal of
126 one component using thermal treatment [29] or dissolution [30].
127 Many of the fiber constructs are supposed to work as implants/tissue scaffolds
128 besides functioning as drug delivery devices. Good mechanical properties are
129 required in order to preserve the structural integrity of the implant. Crosslinking
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130 [31], thermal interfiber bonding (accomplished near the melting temperature of the
131 electrospun polymer and impregnated with a hydrogel that maintains the structure
132 of the scaffold against shrinkage) in order to improve biomechanical properties
Fig. 2 Preparation methods for multicomponent fibers
Fig. 3 Various fiber constructs types
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133 [32] or continuous alignment of electrospun ber yarn obtained by self-bundling
134 electrospinning and further treated by drawing and annealing to improve tensile
135 strength [33] are just some of the available post-processing techniques.
136 2.2 Release Control of Drug Loaded Fibers
137 Fibers can be easily loaded with drug in a similar fashion as multicomponent fibers
138 (Sect. 2.1), the drug being an extra component. By blend electrospinnning, the
139 drug or drug vehicle (such as microspheres [9], nanoparticles [10, 11]) is mixed or
140 phase-separated with the polymer phase and by coaxial electrospinnning, the drug
141 is contained either in the core or in the shell. The advantage of encapsulating the
142 drug in the core or in a vehicle is that usually burst release is minimized/avoided
143 since the drug has longer diffusional paths [11] and the protection of active agents
144 (such as proteins) that are sensitive to organic solvents can be achieved. Moreover,
145 it does not require good interaction between the polymer and drug, but it must
146 show sufficient interfacial compatibility in order to prevent delamination [34]. In
147 contrast, for the cases of drugs loaded by blend electrospinning, poor interaction
148 between the drug and polymer affect the drug distribution in the polymer matrix
149 and consequently the release behavior [35, 36]. Incorporation of bioactive agents
150 that are usually water soluble and can not be dissolved in the same solvent as the
151 polymer (usually organic solvents) can be performed by emulsion electrospining
152 [35, 37].
153 Various post-treatment modalities exist in order to further control the fiber drug
154 release. These can be grouped in two main categories: physical and chemical. The
155 first category includes functionalization of electrospun fibers with biomolecules
156 using coating [16], subcritical carbon dioxide impregnation of electrospun fibers
157 with which it is possible to load drugs and obtain more sustained release profiles in
158 comparison to loading through soaking in drug solution [12]. The second category
159 consists of coating electrospun fiber by chemical vapour deposition in order to
160 prolong the release and avoid burst effect [23], molecular imprinting of fibers
161 (either by loading the template molecule [13] or by loading molecularly imprinted
162 particles [14] inside the fibers during electrospinning) that can selectively rebind
163 the target molecule (biological receptor molecule) and produce targeted drug
164 delivery.
165 Drug delivery systems are intended to deliver well controlled amounts of drug
166 between the minimum effective level and the toxic level during a predetermined
167 time interval [7]. Control of burst effect is essential either to avoid toxicity or to
168 ensure immediate action at the targeted location (as in the case of antibiotics [38]).
169 These are the reasons why the factors that affect the release rate should be con-
170 sidered when designing a new fiber drug delivery system:
171 • Fiber construct geometry (fiber mats or multilayers) and thickness: the drug
172 deposited in single layers is released faster than from multilayers either because
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173 the drug layers are intercalated with non-drug layers that function as barrier to
174 drug release [39] or because the inner layers are not equally exposed to the
175 release medium [40])
176 • Fiber diameter and porosity: a thinner or more porous fiber implies a bigger
177 surface and consequently accelerates the release [41]. However, thicker, but
178 more porous fibers release drug faster than thinner, less porous fibers [42]
179 • Fiber composition: the choice of a degradable polymer will allow release control
180 through a hydrolytic [40] or enzymatic mechanism [36]. Besides, blending
181 various components leads to modulating release capacity [42] either by
182 improving fiber wetting properties (using hydrophilic polymers [43, 44]) or
183 aiding incorporation of drug. In this case, it is possible to avoid burst effect by
184 blending polymers with amphiphilic copolymers which can be compatible with
185 both the drug and the initial incompatible polymer [38]
186 • Fiber crystallinity: initial polymer crystallinity influences the drug release (it
187 blocks the release of the drug from the crystalline domains due to limited water
188 uptake). When the release of drug from the amorphous domains or from the fiber
189 surface is finished, no more drug is released [45]. Moreover, there is an increase
190 in crystallinity during drug release (the drug works as a plasticizer, the polymer
191 chains gain more mobilility and as it is leached out, they crystallize), which
192 decreases the release of residual drug [46]
193 • Fiber mat swelling: water uptake by fibers or by the (macro)pores created
194 between fibers will speed up drug release [47] as the dissolution of drug mol-
195 ecules is the initial step in the release process [48]
196 • Drug loading: higher loadings will produce faster release ([41, 46, 47, 49, 50]);
197 on one hand, at high loadings, there is more surface segregated drug that dis-
198 solves fast and on the other hand, there is an increase in porosity during drug
199 elution proportional to the initial amount of drug [46, 41]
200 • Drug state: in general, drug release was shown to be more sustained, when drug
201 is incorporated in amorphous state [50, 51], than when drug is loaded in crys-
202 talline state [52]. Moreover, it was shown that, even when the drug is in
203 amorphous state, the drug release was faster from the solid solution than from
204 the amorphous dispersion [53]
205 • Drug molecular weight: drugs with smaller volumes will be released faster since
206 they diffuse faster through the aqueous pores created by the water uptake in the
207 fiber [42, 54]
208 • Drug solubility in the release medium: usually, the higher drug solubility, the
209 faster the release [42]
210 • Drug–polymer–solvent interaction: solubility and compatibility of drugs with
211 the polymer and/or the electrospinning solvent is essential since it ensures
212 proper drug incorporation inside the fibers and not on the fiber surface [35, 47,
213 36]. Phase separation between the drug and polymer will produce amorphous or
214 crystalline drug at the fiber surface leading to faster release [55]. Moreover, the
215 interaction between drug and the polymer can block the crystallization of the
216 drug in the fibers, if so desired [53] and can even determine sustained release of
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217 drugs that are present in crystalline state because of hydrogen bonding to the
218 polymer [54]
219 However, in order to predict the outcome of a drug from fibers, it is important to
220 consider the interaction among the various factors in such a complex system. We
221 have already discussed how the drug state controls drug release. However,
222 sometimes high drug loadings are needed for long term applications. Usually, at
223 high loads, the drug will crystallize and/or phase-separate from the polymer and
224 form conglomerates that will produce a heterogeneous distribution of the drug
225 inside the fibers [35, 56] or deposition on the fiber surface [55]. Thus, in long term
226 release applications where high amounts of loaded drug are required, a compro-
227 mise must be found between loading and release rate that change in contrary
228 directions [57]. Careful consideration should also be paid when selecting best pair
229 of polymer and drug, although some applications require material properties that
230 may not match in terms of compatibility the drugs used in the treatment of the
231 targeted diseases.
232 2.3 Release Modeling
233 As summarized in Table 1, a multitude of drug/biomolecules loaded fibers have
234 already been produced. They have been produced either from polymers (synthetic
235 and natural) or inorganic compounds. Most of the release mechanisms were
236 attributed to drug diffusion (as it is the case for most non-biodegradable, non-
237 erodible polymers), solvent diffusion (as in the case of natural polymers that are
238 usually hydrophilic [58]), polymer erosion (as in the case of erodible (bio)poly-
239 mers [53, 54]), polymer degradation (as for hydrolytic or enzymatic degradable
240 polymers) or external triggers (like a magnetic field). In the release system gov-
241 erned by drug diffusion, one has to consider two cases, one in which the diffusion
242 takes place through the bulk of polymer (bulk diffusion) or through a membrane/
243 layer (barrier diffusion, similar to the reservoir devices as in the case of core–shell
244 fibers, composite fibers or multilayered constructs). There are cases in which
245 several mass transport mechanisms superpose. However, in most cases, there is
246 only one that is the ‘‘rate-limiting’’ step. For example, in the case in which dif-
247 fusion is coupled with chemical reaction (in most cases, hydrolysis), if diffusion is
248 faster than the chemical reaction, then mass transfer is controlled by the polymer
249 degradation [59] and when diffusion is not much faster than reaction, then diffu-
250 sion and degradation superpose [40]. In some systems, the release process is
251 composed of sequential stages, with each stage being controlled by a different
252 phenomenon. For example, in the first stage you can have the drug release con-
253 trolled by the polymer erosion and subsequent diffusion, followed by polymer
254 degradation control stage [60].
255 Related to core–shell fibers, we can consider two controlling phenomena: dif-
256 fusion through the polymer shell (barrier diffusion) or partition of the drug from
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257 the core to the shell. The diffusion through the shell polymer should not be too
258 slow, otherwise this diffusion will be rate-limiting step. In this instance, the system
259 behaves as monolith fibers and not core–shell fibers (reservoir system). Shell
260 porosity must also be carefully controlled since the drug from the core will be
261 released through water-filled channels rather than through the barrier/shell poly-
262 mer [34]. Composite fibers that contain drug vehicles such as microspheres and
263 nanoparticles (see Sect. 2.2) are also a type of reservoir system (double barrier
264 system) in which the drug molecules have to diffuse through longer pathways: the
265 polymer comprising the vehicle and the ‘‘shell‘‘ polymer [11].
266 Drug diffusion (more precisely solid state diffusion) was mentioned earlier as
267 one of the most common mechanisms of drug release. There are models that
268 consider diffusion of solutes in polymers insignificant in comparison with diffusion
269 in water-filled spaces in between polymer chains, so they assume that water uptake
270 and subsequent solubilization of the drug is an important step in the release process
271 and it is the solvated molecule that is actually diffusing [61]. This is the
272 assumption behind biphasic diffusion that includes an initial diffusion phase
273 through the polymer (either amorphous or semi-crystalline) and a second diffusion
274 phase through water-filled pores formed in the fiber due to polymer swelling/chain
275 rearrangement or polymer recrystallization [55, 62].
276 The power law equation, which was developed considering that the main
277 mechanism for drug release is drug diffusion through the polymer or solvent
278 diffusion inside the polymer that produces polymer relaxation/chain rearrangement
279 (Eq. 1) is the most widely used equation in works concerning drug release:
280
mt
mtot
¼ a0 þ ktn ð1Þ
2823 where mt=mtot is the fractional release of the drug at time t; a0 is a constant,
284 representing the percentage of burst release, k is the kinetic constant and n is the
285 release exponent, indicating the mechanism of drug release (which can either be
286 Fickian drug diffusion or polymer relaxation and an intermediate case combining
287 the two [63]).
288 Other models consider different phenomena that control the release such as
289 desorption due to the fact that under the assumption of diffusion control, 100%
290 release of the drug is expected, but this was not verified experimentally. In the
291 desorption model, the release is not controlled by diffusion, but by the desorption
292 of the drug from fiber pores or from the fiber surface. Thus, only the drug on the
293 fiber and pore surfaces can be released, whereas the drug from the bulk can only be
294 released when the polymer starts to degrade. These assumptions are similar to the
295 theory of mobile agent, that can be released by diffusion and the immobilized
296 agent, that can be released through degradation [59].
297 The Eq. 2 is based on a pore model, in which the effective drug diffusion
298 coefficient, Deff is considered and not the actual diffusion coefficient in water, D
299 (with Deff=D  1) because desorption from the pore is the rate limiting step and
300 not drug diffusion in water, which is relatively fast.
301
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mt
mtot
¼ a 1  exp  p
2
8
t
sr
  
ð2Þ
3034 where the porosity factor a ¼ ms0=ðms0 þ mb0Þ\1; with ms0 and mb0 being the
305 initial amount of drug at the fiber surface and the initial amount of drug in the fiber
306 bulk, respectively; mt is the drug amount released at time t, while the total initial
307 amount of drug in the fiber is mtot ¼ ms0 þ mb0 and sr is the characteristic time of
308 the release process [73].
309 Various release kinetics exist and the most desirable one is the zero-order
310 kinetics in which the drug is released at constant rate, independent of time (see
311 Fig. 4). Usually, zero-order kinetics is achieved for reservoir systems such as
312 core–shell fibers or composite fibers (see Table 1) in which the drug is properly
313 encapsulated in the core of the fiber or in other vehicles (micro/nanopartilces).
314 Burst stage in this kind of system is diminished (or non-existent) because there is
315 no drug deposited on the surface of the fibers. As the controlling release phe-
316 nomena is drug partition from one phase to another and not diffusion, there is no
317 decrease in release rate over time as expected in a diffusion-controlled system (the
318 release rate depends on the concentration gradient and on the length of diffusion
319 path; as release proceeds, the concentration gradient decreases and the diffusion
320 length increases and both contribute to slowing down the release rate).
321 Other strategies to attain zero-order release include polymer degradation con-
322 trolled release (either accompanied by erosion or not) because then drug is
323 released due to polymer chain cleavage [36, 40]. The drug is released either
324 because the diffusion paths are shortened as degradation takes place (surface
325 degradation) or because porosity is increased due to the leaching of degradation
326 products (bulk degradation) [7]. Another strategy to obtain constant release rate is
327 the use of multilayered constructs [39], in which sequential electrospinning is used
328 to obtain drug loaded layers surrounded by barrier layers.
329 Burst effect can be determined by fiber porosity [34], poor drug solublity in
330 electrospinning solvent [47], poor drug solubility in polymer [36], high drug
331 solubility in release medium [42], heterogeneous drug distribution [35] or surface
332 segregated drug [45]. Most of the times, the polymer and drug selection depend on
333 the properties of the implantation site that need to be matched by the fiber mat and
Fig. 4 Types of release
kinetics
Electrospun Drug-Eluting Fibers for Biomedical Applications
Layout: T1 Standard SC Series ID: MS No.: Vol08Zilberman61Natu
Chapter No.: 56 Date: 20-1-2011 Page: 13/29
A
u
th
o
r 
P
ro
o
f
U
N
C
O
R
R
EC
TE
D
PR
O
O
F
334 the targeted disease. Thus, the burst stage can only be controlled in unicomponent/
335 monolith fibers by manipulating the process parameters and not by the material
336 choice. Ensuring a homogeneous drug distribution [49] (usually by encapsulating
337 drug in amorphous state [50, 46]), low drug loadings [50], or coating the drug
338 loaded fibers [16] are some simple techniques to diminish burst if so desired.
339 3 Results
340 In this chapter we are presenting some results concerning release control
341 in bicomponent fibers composed of poly(e-caprolactone), PCL and Lutrol F127
342 (Lu, poly(oxyethylene-b-oxypropylene-b-oxyethylene)), both semi-crystalline
343 (co)polymers. The properties of the bicomponent fibers were studied in order to
344 determine the effect of electrospinning processing on crystallinity, hydrophilicity
345 and degradation. As both polymers are semi-crystalline, we could test the effect of
346 such organization on the loading and release of drugs. Acetazolamide and timolol
347 maleate were loaded in the fibers in different concentrations (below and above the
348 drug solubility limit in polymers) in order to determine the effect of drug solubility
349 in polymer, drug state, drug loading and fiber composition on fiber morphology,
350 drug distribution and release kinetics. A diffusion model and a desorption model
351 (see Sect. 2.3) were fit to the release data in order to determine the release
352 mechanism
353 3.1 Fiber Mat Degree of Crystallinity, Drug Solubilitity in Polymer
354 and Drug State
355 Solid-state drug polymer solubility and miscibility were shown to influence the
356 drug encapsulation and correlate to drug release [74]. Timolol maleate (experi-
357 mental water solubility =2.74 mg/ml [75]) and acetazolamide (experimental water
358 solubility =0.98 mg/ml [76]) were chosen because of different hydrophilic/
359 hydrophobic character that would allow us to understand how the interactions
360 between the drug and polymers contribute to drug release. The drug solubility is
361 expected to influence the loading and the state of the drug in the fibers as a higher
362 solubility ensures higher loading of drugs in amorphous state. Thus, fibers with
363 low and high drug loadings were prepared corresponding to drug percentages
364 below and above the drug solubility limit, respectively. As a measure of drug–
365 polymer interaction [77], the drug solubility in polymers was determined by dif-
366 ferential scanning calorimetry (DSC) method and the obtained results are pre-
367 sented in Table 2. Acetazolamide had higher solubility than timolol maleate in all
368 fiber compositions probably because of enhanced interaction with the hydroxyl/
369 carboxyl groups of the polymers. Furthermore, a tendency of increase in solubility
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370 was noticed when PCL ratio was increased. An opposite trend was observed for
371 timolol maleate when an increase in solubility was obtained with decrease in PCL
372 content. We will discuss in Sect. 3.4 how the solubility affects the drug release.
373 The polymer degree of crystallinity is known to play an important role in
374 determining water uptake and drug release. Drug release is faster from amorphous
375 than from crystalline regions for semi-crystalline polymers because the lamellae
376 behave as barriers to the diffusion of water and drug [45, 79]. In the case of
377 amorphous polymers, the drug can act as a plasticizer and as it is leached out, the
378 mobile polymer chains rearrange themselves and crystallize [46]. The crystallized
379 matrix becomes microporous [78] and the subsequent drug diffusion takes place
380 through water-filled pores. The polymers used in this work are semi-crystalline and
381 the obtained fibers are expected to be semi-crystalline too. DSC analysis confirmed
382 this hypothesis showing a single or two melting peaks corresponding to the
383 melting of either PCL or Lu. The relative degree of crystallinity of drug loaded
384 fibers is presented in Table 2, where it can be seen that the fibers showed similar
385 degrees of crystallinity regardless the type of loaded drug. The drug appeared to be
386 in amorphous state in fibers with low drug loadings as proven by the absence of
387 drug melting peak (images not shown). In fibers with high loadings, part of the
388 drug was in crystalline form as confirmed by morphological analysis (Sect. 3.2),
389 while the DSC scans of these sample were not conclusive because the peak
Table 2 Degree of crystallinity and drug solubility in polymer(, no processing)
Sample Loading
(%, w/w)
TmðCÞ Rel. degree of
crystallinity (%)
Drug
solubility (%)
Acetazolamide – 271.14 –
Timolol maleate – 205.60 –
PCL 0 60.06 (0.29) 51.37 (0.84) –
25/75 Lu/PCL 0 51.65 (1.37),
59.38 (0.20)
50.97 (2.03) –
50/50 Lu/PCL 0 52.36 (0.67),
59.50 (0.17)
54.83 (1.90) –
Lu 0 55.57 (0.64) 68.51 (2.12) –
PCL, timolol 0.88 (0.01) 60.28 48.22 (0.86) 4.48 (1.11)
25/75 Lu/PCL,
timolol
0.86 (0.02) 56.22 54.71 5.14 (0.94)
50/50 Lu/PCL,
timolol
0.88 (0.04) 55.48 (0.21),
61.28 (0.26)
59.89 (0.24) 6.97 (1.86)
PCL, acetazolamide 1.24 (0.28) 59.99 (0.15) 49.76 (2.87) 16.53 (2.1)
25/75 Lu/PCL,
acetazolamide
1.55 (0.60) 57.64 (2.98),
58.15 (2.93)
55.04 (0.29) 15.94 (4.81)
50/50 Lu/PCL,
acetazolamide
1.16 (0.20) 54.19 (0.08),
60.20 (0.00)
58.94 (0.06) 14.81 (0.8)
PCL, timolol 7.60 (0.32) 60.52 45.96 –
25/75 Lu/PCL,
timolol
6.99 (0.19) 54.36 (0.61),
60.94 (0.21)
52.82 (4.27) –
25/75 Lu/PCL,
acetazolamide
12.67 (0.35) 53.69 (0.87),
60.93 (0.22)
48.15 (4.03) –
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390 corresponding to drug melting was masked by fiber degradation process (that starts
391 at around 250C).
392 3.2 Morphological Analysis and Drug Mapping
393 Morphological differences between samples loaded with the two drugs above or
394 below the solubility limit were assessed by scanning electron microscopy (Fig. 5).
395 In Fig. 5a and b surface images of fibers that contain acetazolamide above solu-
396 bility limit are shown. As the loaded mass of drug was above the solubility limit in
397 the polymer, the drug was expected to be in crystalline form as confirmed by the
398 images where drug crystals were visible outside or inside the fibers. On the other
399 hand, no crystals were observed in the fibers that contain drug in low loadings
400 (Fig. 5c) suggesting that the drug was in amorphous state in the fibers in agree-
401 ment with DSC analysis results (Sect. 3.1).
402 Electron probe microanalysis was performed in order to assess the drug dis-
403 tribution inside the fiber mats. The surface mapping of timolol loaded fibers
404 (Fig. 6b, c) showed relatively homogeneous drug distribution regardless of com-
405 position, while the surface mapping of acetazolamide fibers (Fig. 6a) indicate the
406 presence of drug conglomerates probably due to higher loading. When the drug is
407 above the solubility limit, it will phase-separate and crystallize [56, 35].
408 3.3 Water Contact Angle, Swelling Capacity and Mass Loss
409 Water contact angle is determined by both chemical composition and surface
410 morphology [80]. The surface roughness of the brous mat results in air entrapment
411 between bers, and as such the fiber mats usually present higher contact angle than
412 films with the same composition [81]. Swelling takes place in two different regions
413 of porosity (Fig. 7): water diffuses first in the pores between fibers and later in the
414 fibers themselves.
415 In a fiber mat there are regions in between the fibers that can be occupied by
416 water molecules, while in films or compacts these regions have significantly
417 smaller surface. PCL fibers were highly hydrophobic [a water contact angle of
418 123.18 (0.98)], while the bicomponent fibers were highly hydrophilic (25/75 Lu/
419 PCL had a water contact angle of 18.28 (4.07), while 50/50 Lu/PCL had one of
420 16.25 (2.16)). These results were surprising since in a previous work films with the
421 same compositions presented contact angles in the range 50 to 62 [82]. In
422 bicomponent fibers, the trapped air between the fibers and pores at the fiber surface
423 is easily removed by the incoming water molecules because the water soluble
424 component (Lu) is leaching out. In PCL fibers that showed an increase in water
425 contact angle from 62 (for films) to 123, probably the hydrophobic nature of
426 surface chemical groups (PDLLA was shown to enrich its fiber surface with
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Fig. 5 SEM micrographs of various drug load fibers. a, b 25/75 Lu/PCL, acetazolamide, high
load; c, d 25/75 Lu/PCL, acetazolamide, low load; e, f PCL, timolol, high load; g, h PCL, timolol,
low load
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427 hydrophobic groups [80]) and the trapped air create a barrier to water penetration.
428 Consequently, PCL fibers absorbed water gradually (see Fig. 8a, while the
429 bicomponent fibers presented a sudden increase in water content during the first
430 day (79.0% for 50/50 Lu/PCL and 68.5% for 25/75 Lu/PCL), followed by a
431 constant value thereafter as Lu content in the fiber was diminished due to
432 dissolution.
433 The mass loss plot (Fig. 8b) showed an initial increase in mass loss for
434 bicomponent fibers (42.5% for 50/50 Lu/PCL and 16.6% for 25/75 Lu/PCL), while
435 PCL fibers presented insignificant mass loss (0.45%). Mass loss of PCL is
436 detectable only after the molecular weight reaches a value of 10,000 g/mol [83]
Fig. 6 Sulphur mapping of high loading fibers. a 25/75 Lu/PCL, acetazolamide; b PCL, timolol
(reprinted from [57]); c 25/75 Lu/PCL, acetazolamide (reprinted from [57]), (the scale bar
represents a gradient from 0% (pink) to 100% (red) sulphur content
B
&
W
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T
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437 and thus the initial high mass loss of the bicomponent fibers can only be attributed
438 to the dissolution of Lu as the sample with higher Lu content had the highest mass
439 loss.
440 The morphology of aged fibers (immersed in PBS during 3 days) was also
441 investigated in order to determine the change in fiber structure. In Fig. 9a, it can be
442 noticed the smooth surface of the fibers, while in Fig. 9e pores were observed that
443 were formed due to the dissolution and leaching of Lu. A different appearance was
444 shown by 25/75 Lu/PCL fiber mat (Fig. 9f), where the fibers appeared more
445 wrinkled in comparison with the initial ones and no pores were visible, probably
446 because of lower Lu content.
447 3.4 Drug Release
448 We previously showed how the fiber morphology and drug deposition were
449 affected by the drug state in the fibers: when drug was in amorphous state, it was
450 incorporated inside the fibers, while the drug present in amounts above the solu-
451 bility limit crystallized inside and on the fiber surface (as shown in Fig. 5b). In
452 Fig. 10a and b, the cumulative percentage of released acetazolamide and timolol
453 maleate from fibers with low drug content is presented, while in Fig. 11a, the
454 released drug for fibers with high loadings is shown. It was noticed that fibers with
455 high drug loading presented burst release in contrast with low drug content fibers
456 that showed a more sustained release. The former contained drug crystals at the
457 fiber surface or inside the fibers that were not totally encapsulated and were
458 instantaneously ‘‘released’’, suggesting that the predominant mechanism of release
459 was drug dissolution. On the other hand, in the low loadings fibers, the drug was
Fig. 7 Regions of porosity in
a fiber mat
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460 amorphous and dissolved in the fiber, and as such the release was governed by
461 diffusion.
462 Drug solubility in polymer as well as drug solubility in solution are important as
463 they control the partitioning of the drug from the polymer toward the elution
464 medium [48]. For the same type of fibers, higher percentages of timolol maleate
465 were released in comparison with acetazolamide [for example, in the case of PCL
466 fibers, a ¼ 45:96 (2.92) for timolol and a ¼ 35:14 (1.43) for acetazolamide]. This
467 can be explained by the combined effect of lower polymer solubility and higher
468 water solubility of timolol maleate in contrast with acetazolamide that has higher
(a)
(b)
Fig. 8 Water uptake a and
mass loss b of black square
PCL, black lozenge 25/75 Lu/
PCL, black triangle down 50/
50 Lu/PCL
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469 polymer solubility and lower water solubility. High drug loading and sustained
470 release were observed for formulations using drugs with higher solubility in the
471 polymer [74]. The compatibility between drug and polymer is indeed important as
472 it ensures sustained release when the drug is completely encapsulated and dis-
473 solved in the fiber [45].
474 Fiber composition influenced the release kinetics as drug was slowly released
475 from PCL fibers when compared to bicomponent fibers regardless of the drug type
476 (lower a and k for PCL fiber with timolol than for 25/75 Lu/PCL and 50/70 Lu/
477 PCL fibers with timolol, see Table 3). Certainly, as erosion was very fast
Fig. 9 SEM micrographs of a initial 50/50 Lu/PCL (reprinted from [57]), b initial 25/75 Lu/PCL
(reprinted from [57]), c 50/50 Lu/PCL after 2 days, d 25/75 Lu/PCL after 2 days, e 50/50 Lu/PCL
after 3 days (reprinted from [57]), f 25/75 Lu/PCL after 3 days (reprinted from [57])
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478 (see Sect. 3.3), various pores were created and the drug was released through
479 water-filled pores much faster than from amorphous and crystalline regions of PCL
480 fibers that presented lower porosity [34, 55, 62].
481 A steady state was attained (after approximately 10 days for bicomponent fibers
482 and after 20 days for PCL fibers) without total release of loaded drug (cumulative
483 release percentages smaller than 100%). A fraction of the drug was desorbed from
484 the pores surface and then it diffused through water filled pores, while another
(a)
(b)
Fig. 10 Cumulative release
of acetazolamide a and
timolol maleate b from filled
square PCL, blacklozenge
25/75 Lu/PCL,
blacktriangledown 50/50
Lu/PCL
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485 portion of the drug was trapped between crystalline areas [49, 50] (and inacces-
486 sible to water) and can only be released by polymer degradation (which is
487 insignificant during the time scale of release experiment) [73, 59]. This was not the
488 case for the high drug loading fibers where release was almost complete in the time
489 frame of the experiment. At high loadings, only a small portion of drug was
490 trapped (approximately 10% in the case of PCL, see Fig. 11a). As drug was in
491 higher amount, additional regions of porosity were created after drug dissolution
492 and diffusion besides those created by water uptake and polymer erosion,
493 increasing surface area and enhancing drug release [46, 41].
494 The release kinetics and regression analysis results suggested a three stage
495 release mechanism, with different steps depending on fiber composition. Disso-
496 lution of the surface deposited drug (this stage triggered burst release) was fol-
497 lowed by drug desorption and subsequent diffusion through water-filled pores
498 (created either due to Lu leaching or polymer recrystallization [78]), while the last
499 stage was controlled by polymer degradation. In bicomponent fibers, the polymer
500 erosion stage was dominant during the initial part of the drug release and it was
501 replaced by the above-mentioned three stage mechanism as soon as Lu was lea-
502 ched out from the fibers.
503 4 Summary and Conclusion
504 Electrospinning is a method of obtaining fibers by stretching a polymer droplet
505 using an electrical field. This technology has being expanding due to its simplicity
506 and versatility. In the field of drug delivery, electrospun fibers are an excellent
Table 3 Drug loading and model parameters determined by non-linear regression (, high drug
loading samples)
Sample Desorption model Power law
a s (days) Adj R2 a0 k(dayn) n Adj R2
PCL, timolol 45.96 (2.92) 7.94 (0.03) 0.86 5.08 (3.63) 11.51 (3.23) 0.37 (0.06) 0.92
25/75 Lu/PCL,
timolol
50.41 (2.95) 0.87 (0.76) 0.00 26.93 (2.71) 12.58 (2.72) 0.26 (0.05) 0.90
50/50 Lu/PCL,
timolol
64.60 (2.99) 1.10 (0.40) 0.33 26.34 (3.74) 25.97 (4.09) 0.15 (0.03) 0.90
PCL, timolol 87.29 (0.46) 0.02 (6.51) 0.55
25/75 Lu/PCL,
timolol
98.55 (0.27) 0.01 (8.66) 0.40
PCL,
acetazolamide
35.14 (1.43) 4.11 (0.05) 0.92 0.00 (4.76) 17.09 (4.88) 0.24 (0.06) 0.82
25/75 Lu/PCL,
acetazolamide
40.59 (0.62) 0.37 (1.48) 0.96 1.16 (1.66) 36.60 (1.92) 0.03 (0.01) 0.98
50/50 Lu/PCL,
acetazolamide
30.50 (1.16) 0.91 (0.46) 0.54 10.99 (1.06) 14.49 (1.18) 0.12 (0.02) 0.96
25/75 Lu/PCL,
acetazolamide
98.08 (0.24) 0.05 (0.59) 0.99
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507 choice because of easy drug entrapment, high surface area, morphology control
508 and biomimetic characteristics. Multicomponent bers have attracted special
509 attention because new properties can be obtained through the combination of
510 different materials. There are several factors that can be manipulated in order to
511 control the drug release from electrospun fibers. Fiber construct geometry and
512 thickness, fiber diameter and porosity, fiber composition, fiber crystallinity, fiber
513 swelling capacity, drug loading, drug state, drug molecular weight, drug solubility
514 in the release medium, drug–polymer–electrospinning solvent compatibility are
515 some of the process variables that can be optimised during method development.
(a)
(b)
Fig. 11 Cumulative release
of high loadings fibers a from
black square 25/75 Lu/PCL
with acetazolamide,
blacklozenge PCL with
timolol, blacktriangledown
25/75 Lu/PCL with timolol
and cumulative release of low
loadings fibers and curves
corresponding to non-linear
fit of Eq. 2) b from
blacksquare PCL with
acetazolamide, blacklozenge
PCL with timolol,
blacktriangledown 25/75
Lu/PCL with timolol
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516 We presented in this chapter how drug release control can be achieved in
517 bicomponent fibers through the manipulation of drug solubility in polymer, drug
518 state and loading. The restraint of burst stage is essential in order to avoid toxicity
519 at the implantation site and to ensure long-term delivery. Fibers were obtained by
520 electrospinning of two semi-crystalline (co)polymers, PCL and Lu, and were
521 loaded with two drugs, acetazolamide and timolol maleate, in concentrations
522 below and above the drug solubility limit in polymer. Morphological analysis
523 showed that fibers with high drug loadings (above solubility limit) had drug
524 crystals inside and outside the fibers, while fibers with low drug content (below
525 solubility limit) had drug encapsulated in amorphous form.
526 The high loadings fibers showed higher extent of burst and shorter periods of
527 release than low drug content fibers, suggesting that loading and drug encapsu-
528 lation in either crystalline or amorphous form are interrelated and control the
529 release rate, especially in the burst stage. Thus, in long term release applications
530 where high amounts of loaded drug are desirable, a compromise must be found in
531 order to balance the loading and release rate that seem to vary in opposite
532 directions according to the present study. Timolol maleate was released faster than
533 acetazolamide in the same type of fibers and similar loadings, indicating that drug
534 solubility in polymer influenced the partition of drug between polymer and elution
535 medium. The fiber composition also controlled drug release, since release was
536 slower from PCL fibers than from bicomponent fibers regardless of the drug type.
537 By choosing the polymers making up the bicomponent fibers and their ratio, the
538 magnitude of the various release stages can be controlled, attaining the desired
539 release kinetics.
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